Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...

The FTC reports that from 2017 to 2022 the three largest ... by then providing the drug to patients without the rebate the PBM can pocket the difference through spread pricing.

PBM's serve as middlemen between drug makers, insurers, and pharmacies. A new report from the FTC claims the companies made more than seven-billion dollars by marking up the prices of generic ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...